The University of Notre Dame Australia

ResearchOnline@ND
Health Sciences Papers and Journal Articles

School of Health Sciences

2013

Online prostate cancer screening decision aid for at-risk men: A
randomized trial
Kaaren J. Watts
Bettina Meiser
Claire E. Wakefield
Alexandra Barratt
Kirsten Howard

See next page for additional authors

Follow this and additional works at: https://researchonline.nd.edu.au/health_article
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons
This article was originally published as:
Watts, K. J., Meiser, B., Wakefield, C. E., Barratt, A., Howard, K., Cheah, B. C., Mann, G. J., Lobb, E., Gaff, C., & Patel, M. I. (2013). Online
prostate cancer screening decision aid for at-risk men: A randomized trial. Health Psychology, Advanced Online, 1-13.
http://doi.org/10.1037/a0034405

This article is posted on ResearchOnline@ND at
https://researchonline.nd.edu.au/health_article/124. For more
information, please contact researchonline@nd.edu.au.

Authors
Kaaren J. Watts, Bettina Meiser, Claire E. Wakefield, Alexandra Barratt, Kirsten Howard, Benjamin C.
Cheah, Graham J. Mann, Elizabeth Lobb, Clara Gaff, and Manish I. Patel

This article is available at ResearchOnline@ND: https://researchonline.nd.edu.au/health_article/124

Health Psychology
Online Prostate Cancer Screening Decision Aid for
At-Risk Men: A Randomized Trial
Kaaren J. Watts, Bettina Meiser, Claire E. Wakefield, Alexandra L. Barratt, Kirsten Howard,
Benjamin C. Cheah, Graham J. Mann, Elizabeth A. Lobb, Clara L. Gaff, and Manish I. Patel
Online First Publication, November 25, 2013. doi: 10.1037/a0034405

CITATION
Watts, K. J., Meiser, B., Wakefield, C. E., Barratt, A. L., Howard, K., Cheah, B. C., Mann, G. J.,
Lobb, E. A., Gaff, C. L., & Patel, M. I. (2013, November 25). Online Prostate Cancer Screening
Decision Aid for At-Risk Men: A Randomized Trial. Health Psychology. Advance online
publication. doi: 10.1037/a0034405

Health Psychology
2013, Vol. 32, No. 11, 000

© 2013 American Psychological Association
0278-6133/13/$12.00 http://dx.doi.org/10.1037/a0034405

This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.

Online Prostate Cancer Screening Decision Aid for At-Risk Men:
A Randomized Trial
Kaaren J. Watts and Bettina Meiser

Claire E. Wakefield

University of New South Wales

University of New South Wales and Sydney Children’s Hospital

Alexandra L. Barratt and Kirsten Howard

Benjamin C. Cheah

University of Sydney

University of New South Wales

Graham J. Mann

Elizabeth A. Lobb

University of Sydney at Westmead Millennium Institute

Calvary Health Care Sydney and Cunningham Centre for
Palliative Care and University of Notre Dame, Sydney

Clara L. Gaff

Manish I. Patel

Walter and Eliza Hall Institute of Medical Research and
University of Melbourne

University of Sydney

Objective: This study examines the efficacy of an online screening decision aid (DA) for men with a family
history of prostate cancer. Methods: Unaffected Australian men (40 –79 years) with at least one affected
relative completed the first online questionnaire, were randomized to read either the tailored DA (intervention)
or nontailored information about prostate cancer screening (control), then completed a questionnaire postreading and 12 months later. The primary outcome was decisional conflict regarding prostate specific antigen
(PSA) testing. The impact of the DA on longitudinal outcomes was analyzed by using random intercept mixed
effects models. Logistic and linear regressions were used to analyze the impact of the DA on screening
behavior and decision regret. Stage of decision-making was tested as a moderator for decisional conflict and
decision regret. The frequency of online material access was recorded. Results: The DA had no effect on
decisional conflict, knowledge, inclination toward PSA testing, accuracy of perceived risk, or screening
behavior. However, among men considering PSA testing, those who read the DA had lower decision regret
compared with men who read the control materials, ␤ ⫽ 0.34, p ⬍ .001, 95% confidence interval (CI) ⫽ [.22,
.53]. Conclusions: This is the first study to our knowledge to evaluate the uptake and efficacy of an online
screening DA among men with a family history of prostate cancer. Men who were undecided about screening
at baseline benefitted from the DA, experiencing less regret 12 months later. In relation to decisional conflict,
the control materials may have operated as a less complex and equally informative DA.
Keywords: prostate cancer, prostate cancer screening, family history, decision aid, risk, online
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Compared with receiving treatment at the time of clinical diagnosis, the balance of evidence suggests that screening for early
detection and treatment of some occult cancers (e.g., cervical and
colorectal cancers) improves patient prognosis (Andrae et al.,
2012; Towler et al., 1998). This is not the case for prostate cancer,
where there are uncertain benefits and harms of screening with
prostate specific antigen (PSA) testing and/or digital rectal examination (DRE). The differing findings of two large randomized
controlled trials examining the potential benefits of screening may
have fuelled, rather than resolved, the debate (Barratt & Stockler,
2009). The U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO)
Cancer Screening Trial randomized over 76,000 men to receive
either annual screening (PSA testing and DRE) or usual care. After
7 years of follow-up, the rate of death from prostate cancer did not
differ significantly between the two study groups (Andriole et al.,
2009). The trial, however, likely underestimated the effects of
screening because of substantial contamination by off-study
screening in the control arm (Barratt & Stockler, 2009). The
European Randomized Study of Screening for Prostate Cancer
(ERSPC) trial randomly allocated over 160,000 men to 4-yearly
screening with PSA testing or usual care, with follow-up from
3–15 years. While a small survival benefit was associated with
annual PSA testing, screening also resulted in more frequent
diagnoses and patients with indolent cancer receiving potentially
unnecessary treatment (Barratt & Stockler, 2009; Schröder et al.,
2009).
In view of this uncertainty, professional organizations encourage clinicians to engage patients in either informed or shared
decision-making about prostate cancer screening (Woolf & Krist,
2009). The American Cancer Society (Wolf et al., 2010) recommends the use of patient decision aids (DAs) to present balanced
evidence-based information regarding prostate cancer screening to
facilitate informed decision-making. A DA contains information
about treatment options and the relevant outcomes and assists
patients with making informed choices that are consistent with
their personal values (Barratt, Trevena, Davey, & McCaffery,
2004; Elwyn et al., 2006). A systematic review of prostate cancer
screening DAs found that they improved patient knowledge of
screening, led patients to feel more informed about making a
decision, and decreased their intention to be screened and their
participation in screening (Volk et al., 2007).
The Internet provides an easy, automated, anonymous, and
cost-effective means of delivering evidence-based health information (Krist, Woolf, Johnson, & Kerns, 2007; Ziebland et al.,
2004). Health information can be readily customized on the
Internet by using either targeted approaches (focus on groups)
or tailored approaches (individual). Tailoring is the process of
providing individualized messages. Tailored health information
requires an assessment in which data from a specific individual
and related to a given health outcome are used to determine the
most appropriate messages to meet that person’s needs (Rimer
& Kreuter, 2006). Six previous studies have evaluated the
efficacy of Web-based DAs among men (Allen et al., 2010;
Ellison et al., 2008; Evans et al., 2010; Frosch, Kaplan, &
Felitti, 2003; Ilic, Egberts, McKenzie, Risbridger, & Green,
2008; Krist et al., 2007), but only two of these contained
content group tailored to a man’s family history of prostate
cancer (Ellison et al., 2008) and individually tailored according
to personal risk factors (Allen et al., 2010). Both DAs signifi-

cantly enhanced knowledge scores among men allocated to the
intervention compared with controls in both studies.
To date, however, no studies have evaluated an online DA with
risk information individually tailored to the risk status of unaffected men with a family history of prostate cancer. Tailored risk
information is important given that men with a relevant family
history overestimate their cancer risk (Miller et al., 2001), and they
report unmet information needs (Wakefield et al., 2008a). Such
men are also more likely to undergo PSA testing (McDowell,
Occhipinti, Gardiner, Baade, & Steginga, 2009). Reviews of primary and secondary prevention programs have found that tailored
information is more likely to be read and recalled, and has a greater
impact on people’s intentions and behavior, than generic information (Kroeze, Werkman, & Brug, 2006; Skinner et al., 2002;
Walters, Wright, & Shegog, 2006). Tailoring is also likely to
increase perceived interest in the messages being conveyed (Skinner et al., 2002; Walters et al., 2006).
The potential moderating influence of a man’s stage of
decision-making (SDM) about prostate cancer screening has not
been examined in previous DA trials. SDM refers to an individual’s readiness to engage in decision-making, progress in
making a choice, and willingness to (re)consider options
(O’Connor, 2000). In a study conducted among 214 female
breast cancer patients who were carriers of a BRCA1 or BRCA2
mutation, baseline decision status moderated the impact of a
tailored interactive DA designed to assist with risk management
options (Schwartz et al., 2009). After disclosure of genetic test
results, women were randomized to receive the tailored DA
(CD-ROM format) plus usual care, or usual care only. Among
women who at baseline had not yet made a final decision about
how to manage their breast cancer risk, use of the DA resulted
in a significant reduction in decisional conflict, an increase in
decision satisfaction, and an increase in the likelihood of reaching a final risk management decision (Schwartz et al., 2009).
These effects were not evident for participants who had already
made a decision at baseline. Therefore, SDM about PSA testing
may influence whether a DA will be of benefit to at-risk men in
relation to decisional uncertainty and subsequent decision regret regarding screening choice.
The objective of this randomized controlled trial was to evaluate
the efficacy of an online individually tailored prostate cancer
screening DA (intervention) compared with online nontailored
educational materials about prostate cancer screening (control) on
decision-related outcomes and screening behavior among unaffected men with a family history of prostate cancer.
It was hypothesized that participants allocated to the DA, compared with participants in the control group, would across time
(baseline to 12 months): (a) show a larger reduction in decisional
conflict and a greater increase in knowledge about prostate cancer
screening; (b) be more accurate about their perceived risk of
developing prostate cancer; and (c) be more confident about their
propensity toward or against screening; It was further hypothesized that 12 months after the intervention when men have had
time to make a decision and to reflect upon their screening choice,
participants in the DA group would: (d) be less likely to have had
a PSA test; and (e) show greater change in decisional conflict and
lower decision regret, with this effect moderated by stage of
decision making about PSA testing.
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Method
The Ottawa Decision Support Framework (O’Connor et al., 1998)
provided the framework for the development of the DA. The framework identifies several determinants of health care decisions that may
be problematic and modifiable by DAs, including poor knowledge,
unrealistic expectations, high uncertainty, and unclear values
(O’Connor et al., 1999). In the current study, we developed a DA that
specifically targeted several potential barriers to at-risk men’s decision about prostate cancer screening, including insufficient knowledge about the risks and benefits of screening, decisional uncertainty,
unclear values, and a tendency to overestimate one’s risk of developing prostate cancer (Miller et al., 2001; Wakefield et al., 2008a). Full
details of the development and pilot-testing of the DA are available
elsewhere (Wakefield et al., 2011).

Materials
Tailored decision aid (intervention). The online DA comprised 25 screens including the home page, five “requested reading” screens, and six “optional reading” screens; the remaining
screens were related to the study. The requested reading screens
included an interactive personal worksheet and a values clarification exercise (VCE; 4 additional screens). Participants were also
presented with individually tailored statistics about their chances
of being diagnosed with, and dying from, prostate cancer, with and
without screening based upon a combination of their age and the
number of their first-degree relatives (FDR) and/or second-degree
relatives (SDR) previously diagnosed with prostate cancer (Howard, Barratt, Mann, & Patel, 2009).
Nontailored materials (control). It has been argued that a
psychosocial intervention should be compared with a comparison
condition that closely resembles the intervention but without the
elements thought to be actively therapeutic (Shapiro & Shapiro,
1997); such a condition is also referred to as an attention control.
Hence, the information in the control materials (18 screens) was
identical to that contained in the DA, with the following exceptions: (a) the personal worksheet, (b) the two example worksheets,
(c) a screen entitled “is it common to inherit an increased chance
of developing prostate cancer?” and (d) the tailored risk statistics.
There were three “requested reading” screens and five “optional
reading” screens.
The online materials also included an in-text glossary of terms
and navigation instructions for both groups. Supplementary Figure
1 shows the content of the DA and the control materials.

Participants
Eligible participants were recruited from May 2010 to September 2011. Men who (a) had not been diagnosed with prostate
cancer, (b) were aged 40 –79 years, (c) had at least one FDR or
SDR with a previous diagnosis of prostate cancer, (d) were proficient in English, and (e) were able to give informed consent were
eligible to participate. The study was approved by the appropriate
institutional review board. In view of the low participation rate in
the pilot phase of the DA (Wakefield et al., 2011), multiple
recruitment strategies were employed. As an incentive to participate, AUD20 was donated to the Cancer Council NSW for prostate
cancer research for every man who enrolled in the trial. Unaffected
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Australian males in the community were invited to participate in
advertisements placed in the weekend edition of three Australian
newspapers and in a radio broadcast. A link to the study website
(www.prostatescreening.org.au) was placed on the Cancer Council
NSW website; and in the electronic newsletters of Rotary Australia, and the University of New South Wales, Sydney. A targeted
mail-out of a study package was also sent to patients diagnosed
with prostate cancer since 2008 who had attended a private urology clinic, located in Sydney NSW, to give to their male relatives.

Procedure
Contingent upon a participant’s responses to three initial eligibility questions (age and personal and family history of prostate
cancer), participants in the intervention group were automatically
directed to 1 of 8 versions of the DA containing risk statistics
regarding the chance of being diagnosed with, or dying from,
prostate cancer with or without annual screening over the next 10
years, tailored to their age group (40 – 49 years, 50 –59 years,
60 – 69 years, or 70 –79 years) and risk status (moderate or high
risk). Risk status was determined using published estimates of the
numeric increase in risk for differing types and numbers of affected relatives (Howard et al., 2009). Participants were classified
as moderate risk if they had: either one FDR or one SDR previously diagnosed with prostate cancer, or two SDRs previously
diagnosed with prostate cancer, or one FDR and one SDR affected
with prostate cancer. Participants were classified as high risk if
they had two affected FDRs or three or more FDRs or SDRs
affected (Wakefield et al., 2011). Supplementary Figure 2 illustrates risk classification. Participants were not provided with feedback about their risk status.
Computerized blocked randomized assignment was used to allocate participants individually, with each block of six participants
randomized to 1 of 2 parallel groups—the intervention or control
group. For allocation of the participants, a computer-generated list of
random numbers was used, except when the number of participants in
one condition exceeded the other condition by more than three;
whenever this occurred, the next allocation was to the underrepresented group, with random allocation recommencing after that.
This method was employed to achieve balanced randomization (1:1).
Allocation concealment was achieved through the automated randomization process such that at the time of allocation, neither participants
nor the study coordinator knew which treatment arm participants were
allocated to. It was not possible to blind participants or the data
analyst to treatment arm allocation.
Men registered to participate by entering an e-mail address and
a password at the study website, and then provided informed
consent. After account activation, men were asked to answer the
eligibility questions. Ineligible men were unable to proceed and
were directed to general information about prostate cancer screening (Cancer Council NSW, 2009). Eligible men were instructed to
complete the first questionnaire (Time 1), read the “requested
reading” sections, and then immediately afterward complete the
second questionnaire (Time 2). Participants allocated to the DA
were also asked to complete the personal worksheet. At 12 months
an automated e-mail prompted men to complete the third questionnaire (Time 3). A further two reminder e-mails were sent by
the study coordinator 2 and 4 weeks after the automated e-mail.
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Outcomes
Primary outcome. Decisional conflict (DC) regarding PSA
testing was assessed at all time points using the validated low
literacy version of the Decisional Conflict Scale (DCS; O’Connor,
1993 [updated 2010]; O’Connor, 1995). We elected to use the low
literacy version of the DCS because it had fewer items and was
more suited to an online format, minimizing participant burden.
Ten items assessed participants’ uncertainty regarding current intention about having a PSA test in the next year with response
options of 0 ⫽ “Yes”, 2 ⫽ “Unsure,” and 4 ⫽ “No.” Scores were
converted to a 0 –100 scale and ranged from 0 (no DC) to 100
(extremely high DC). Cronbach’s alpha in the present study was
.91 at baseline.
Secondary outcomes. Knowledge of prostate cancer screening, perceived risk of developing prostate cancer, and inclination
toward having a PSA test were assessed at all time points. Screening behavior was assessed at Times 1 and 3. Decision regret
regarding PSA testing was assessed at Time 3.

Measures
Demographic data collected included employment status, occupation, marital status, language spoken at home, and highest level
of education completed.
Knowledge. Ten items were developed for this study based
upon expert input from the researchers and a review of the literature.
The items included: six concept items - two of these items were drawn
from Radosevich et al. (2004), and four numeric items were adapted
from Mathieu et al. (2007). The items were designed to assess understanding of the (a) pros and cons of PSA testing (items 1–3), (b)
inheritance and relevance of a family history of prostate cancer (items
4 – 6), and (c) the chances of being diagnosed with or dying from
prostate cancer with or without screening (items 7–10). Details of the
items and the response options are in Supplementary Table 1. A score
of one was given for a correct answer and a score of zero for an
incorrect or “don’t know” response. Total knowledge score was
calculated by summing the correct responses (range ⫽ 0 –10). Cronbach’s alpha in the present study was .61 at baseline.
Perceived risk. A single item was adapted from (Kasparian,
Meiser, Butow, Simpson, & Mann, 2009). Participants were asked
to rate their chance of developing prostate cancer on an 11-point
visual analogue scale where 0 ⫽ “no chance,” and 100 ⫽ “100%
chance, meaning you will definitely get it.”
Inclination regarding PSA testing. Using a single item
adapted from O’Connor (1996a [modified 2003]), participants
were asked “At this point in time, are you leaning toward wanting
to have a PSA test, or not?” (response options 1 ⫽ “I am leaning
toward having a PSA test”; 2 ⫽ “I am not sure yet”; 3 ⫽ “I am
leaning toward NOT having a PSA test”).
Stage of decision making. A single item assessed men’s
SDM (O’Connor, 2000 [modified 2003]). Participants were asked
“At the moment, how far along are you with your decision regarding PSA testing?” Response options 1– 4 included: “I have not yet
thought about the options”; “I am considering the options”; “I am
close to choosing an option”; and “I have already made a choice.”
Screening behavior. A single item was administered at baseline. A similar item has been used in other studies to assess prostate
cancer screening behavior (Glenn et al., 2012): “Have you ever had a
PSA test to screen for prostate cancer?” (Response options 1– 4

included: “No”; “Yes, I had a PSA test more than 12 months ago”;
“Yes, I have had one PSA test in the last 12 months”; and “Yes, I have
had more than one PSA test in the last 12 months.” At 12 months,
participants were asked whether they had had a PSA test since reading
the online materials and if so, whether they had had one or more PSA
tests in that period (response options 1–3: “No”; “Yes, I have had one
PSA test in the last 12 months”; “Yes, I have had more than one PSA
test in the last 12 months”).
Decision regret. Distress or remorse following a decision about
PSA testing was assessed at 12 months using the validated Decision
Regret Scale (Brehaut et al., 2003; 5 items, response options: 1 ⫽
“strongly agree” through 5 ⫽ “strongly disagree”). Scores were
converted to a 0 –100 scale, and each item was summed and averaged
to obtain a final score: 0 (no regret) to 100 (high regret; O’Connor,
1996b [updated 2003]). Cronbach’s alpha in the present study was
.89.
A target sample size of 64 participants in each group provided
sufficient power (80%) to detect a 0.5 effect size difference between groups (i.e., a medium effect size; Cohen, 1988) in the
primary outcome variable (decisional conflict). A medium effect
size was elected because this has been considered clinically important in a range of cancer-related scenarios (Norman, Sloan, &
Wyrwich, 2003).

Data Analyses
An intention-to-treat analysis was undertaken of all eligible
participants who were randomized and who completed Questionnaire 1 irrespective of whether they read the online materials. To
assess the impact of the DA on accuracy of perceived risk, participants were classified as either “accurate”, or “inaccurate” (an
underestimator or an overestimator; Meiser et al., 2001). Accuracy
of perceived risk was determined by comparing each participant’s
actual (objective) risk of prostate cancer with his perceived risk.
Actual risk was calculated by multiplying each individual’s relative risk (RR) of prostate cancer, based on his self-reported family
history (i.e., RR of 2.0 or 5.0) by 0.11 (the average lifetime risk of
prostate cancer of 1 in 9; Australian Institute of Health and
Welfare, 2007). Participants whose perceived risk fell either one
response option below or above their objective risk were categorized as accurate (Meiser et al., 2001). For example, a man at
moderate risk (with an actual risk of 0.22 [RR 2.0 ⫻ 0.11]) was
categorized as accurate if he rated his perceived risk anywhere
between 10% and 30%. Participants whose perceived risk fell
more than one response option below or above their objective risk
were categorized as inaccurate (n ⫽ 6 underestimators, n ⫽ 45
overestimators). Because of the small number of “underestimators,” all inaccurate responses were combined for the data analyses.
Random intercept linear mixed effects models were used to
analyze longitudinal continuous outcomes—DC and knowledge
about prostate cancer screening. Linear regression with adjustment
for baseline DC was used to analyze decision regret (measured at
12 months), while logistic regression was used to evaluate the
effect of the DA on screening behavior. Decisional conflict, decision regret, and knowledge scores were log-transformed to reduce
data skewness and to improve model fitting. Before logtransformation of DC and decision regret scores, a value of 5 was
added to the original scores, because the minimum was zero. This
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did not change interpretation, because their original scales were
arbitrary. Population-averaged logistic generalized linear mixed
effects models were used to analyze longitudinal binary outcomes,
inclination, and accuracy of perceived risk.
Unadjusted analyses and then adjusted analyses were performed
to investigate the effects of additional covariates that may have
predicted the outcome. To account for curvilinear changes in the
outcome measures over time, quadratic time terms were included
in the models where necessary. To investigate the effect of the DA,
time by treatment group interaction terms were also included in the
statistical models. Tests were two-sided, and p values ⬍ .05 were
considered significant.

Results
One hundred thirty-eight eligible men were randomized (n ⫽ 69
Intervention and n ⫽ 69 Control) and completed the baseline
questionnaire (Time 1); 102 participants completed the second
questionnaire (Time 2), and 90 completed the third questionnaire
(Time 3). Figure 1 summarizes the flow of recruitment.

Sample Characteristics
The baseline sample characteristics are presented in Table 1. A
direct logistic regression was performed to assess whether a number of factors predicted attrition. Participant attrition over the study
did not differ significantly as a function of age (less than 60 years,
60 years or over), B ⫽ .04, odds ratio [OR] ⫽ 1.04, p ⫽ .07 (95%
CI ⫽ 0.99 –1.08); level of education (nonuniversity qualified,
university qualified), B ⫽ ⫺.44, OR ⫽ .64, p ⫽ .26 (95% CI ⫽
.29 –1.39); or risk group (moderate risk, high risk), B ⫽ ⫺.56,
OR ⫽ .58, p ⫽ .28 (95% CI ⫽ .21–1.56). Proportion of total
screens accessed and group allocation did predict attrition. Respondents in the DA group were less likely to complete all questionnaires, B ⫽ ⫺.96, OR ⫽ .38, p ⬍ .05 (95% CI ⫽ .17–.85), and
respondents who accessed a larger proportion of total screens were
more likely to complete the study, B ⫽ .04, OR ⫽ 1.04, p ⬍ .001
(95% CI ⫽ 1.02–1.06).

Use of the Website and Reading of the Materials
The mean number of requested reading screens accessed was
6.43 of 9 screens by men in the intervention group (SD ⫽ 3.24):
and 2.64 of 3 screens by controls (SD ⫽ 0.87). The proportion of
men who accessed each of the requested reading screens and
optional reading screens on the website is presented in Table 2. Of
the men who completed the second questionnaire, the majority
reported having read the information materials “from the first page
to the last page” or “quite thoroughly” (74%). Of the men allocated
to read the DA, 51% completed the VCE.
Means for continuous variables and proportions for dichotomous variables are presented in Table 3.

Primary Outcome: Decisional Conflict
Using a linear mixed effects model with random baseline measurements, the effect of the intervention on DC was not statistically
significant after adjusting for age and SDM (␤ ⫽ 0.97, p ⫽ .47),
95% CI ⫽ [.90, 1.05]. SDM did not moderate the effect of the
intervention on DC (␤ ⫽ 1.04, p ⫽ .33), 95% CI ⫽ [.96, 1.13]. In
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the interests of parsimony, SDM was, therefore, removed from the
model, and the model adjusting for age only is reported hereafter.
The quadratic effect of time was significant (␤ ⫽ 1.07, p ⬍ .001),
95% CI ⫽ [1.05, 1.09], indicating that changes in decisional
conflict scores were curvilinear over time for both groups. Specifically, DC decreased substantially immediately after reading the
education materials and this effect was sustained at 12 months.

Secondary Outcomes
Knowledge of prostate cancer screening. The DA had no
significant effect on knowledge after adjusting for language spoken at home (␤ ⫽ 1.0, p ⫽ .88), 95% CI ⫽ [.99, 1.01]. The
quadratic effect of time was significant (␤ ⫽ 0.98, p ⬍ .001), 95%
CI ⫽ [.98, .99] for both groups taken together, suggesting that the
longitudinal change in knowledge was curvilinear (i.e., knowledge
increased immediately after reading the materials and this effect
was sustained at 12 months).
Accuracy of perceived risk. There was no effect of the DA
on change in accuracy of perceived risk after adjusting for education, B ⫽ 0.02, p ⫽ .62, OR ⫽ 1.02, 95% CI ⫽ [.95, 1.09]. A
logistic mixed effects model showed a significant quadratic effect
of time for both groups collectively, indicating curvilinear change
over time in accuracy, B ⫽ ⫺0.05, p ⬍ .05, OR ⫽ 0.96, 95% CI ⫽
[.92, .99]. In the intervention group, the pattern of data suggest that
the proportion of men who were accurate about their perceived risk
increased immediately after reading the information materials
(from 40% to 68%), but the proportion then decreased toward
baseline levels (48%) at 12 months.
Inclination regarding PSA testing. There was no effect of
the DA on inclination after adjusting for education, B ⫽ ⫺0.02,
p ⫽ .85, OR ⫽ 0.98, 95% CI ⫽ [.84, 1.15], and for both groups
together, participants’ inclination regarding PSA testing did not
change over time, B ⫽ 0.10, p ⫽ .47, OR ⫽ 1.10, 95% CI ⫽ [.85,
1.42].
Screening behavior. At baseline, 62% of controls and 56% of
men in the intervention group had had at least one PSA test in the
previous 12 months. At Time 3, the proportions for each group
were 75% and 69%, respectively. After adjusting for baseline DC
and age, the DA had no effect on screening behavior at 12 months,
B ⫽ ⫺0.17, p ⫽ .57, OR ⫽ 0.85, 95% CI ⫽ [.48, 1.51].
Decision regret. Compared with the control materials, the DA
resulted in lower decision regret at 12 months’ follow-up after
adjusting for baseline DC and education (␤ ⫽ 0.34, p ⬍ .001),
95% CI ⫽ [.22, .53]. The intervention effect was modified by
SDM (␤ ⫽ 3.28, p ⬍ .001), with a significant effect among men
who were undecided about PSA testing at baseline (␤ ⫽ 0.34, p ⬍
.001). Among men who had not yet made a choice about PSA
testing, decision regret was 63% lower at follow-up for those who
read the DA (M ⫽ 11.7, SD ⫽ 11.7) compared with men who read
the control materials (M ⫽ 31.4, SD ⫽ 7.5).
A summary of the results of the data analyses are provided in
Table 4.

Discussion
At-risk men face a complex, value-laden decision about prostate
cancer screening because there is no clear evidence that the benefits of screening outweigh the harms. Guided by the Ottawa
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Figure 1. Recruitment flow for the randomized trial comparing an online tailored prostate cancer screening
decision aid with online nontailored control materials.

Decision Support Framework, we tested the impact of an individually tailored online decision aid designed to address several
potential barriers to informed decision making among at-risk men.
Contrary to expectation, there was no significant impact of the
DA on decisional conflict, knowledge, or accuracy of perceived

risk. Decisional conflict scores decreased and knowledge scores
increased across time for both groups. There was a trend for the
proportion of men who were accurate about their perceived risk of
developing prostate cancer to increase immediately after the intervention, but this benefit was not maintained at 12 months. The
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Table 1
Demographic Characteristics of Participants at Baseline (N ⫽ 138)
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Description

Control (N ⫽ 69) Intervention (N ⫽ 69) Total (N ⫽ 138)

Age in years, M (SD)
Relationship status, n (%)
Never married
Widowed/separated or divorced
Married/cohabiting
Language spoken at home, n (%)
English
Language other than English
Family history of prostate cancer, n (%)
One first- or second-degree relative
Two or more first- or second-degree relatives
Highest level of education, n (%)
High school only
Certificate/diploma
Undergraduate degree
Postgraduate degree
Employment status, n (%)
Employed (full-time or part-time)
Retired
Unemployed

direction of decisional conflict and knowledge scores accords with
earlier studies in which patient education materials about prostate
cancer screening in a variety of formats reduced uncertainty and
improved knowledge among unaffected men (Davison, Kirk,
Degner, & Hassard, 1999; Krist et al., 2007; Taylor et al., 2006).
The absence of an intervention effect on decisional conflict, knowledge, and accuracy may have occurred because the control materials
had similar content to the DA, with the exception of the interactive
personal worksheets, the tailored risk information, and the example
worksheets. It appears that the tailored components unique to the DA
did not contribute to change over and above the educational components of the materials. The control materials, therefore, may have
functioned as a less detailed DA by providing men with non tailored
information about the benefits and harms of screening, thus impacting

56.5 (9.9)

55.4 (9.0)

55.9 (9.4)

3 (4.3)
8 (11.6)
58 (84.1)

1 (1.4)
10 (14.5)
58 (84.1)

4 (2.9)
18 (13.0)
116 (84.1)

64 (92.8)
5 (7.2)

63 (91.3)
6 (8.7)

127 (92.0)
11 (8.0)

50 (72.5)
19 (27.5)

47 (68.1)
22 (31.9)

97 (70.3)
41 (29.7)

12 (17.4)
20 (29.0)
25 (36.2)
12 (17.4)

8 (11.6)
21 (30.4)
17 (24.6)
23 (33.3)

20 (14.5)
41 (29.7)
42 (30.4)
35 (25.4)

49 (71.0)
20 (29.0)
0 (0)

51 (73.9)
16 (23.2)
2 (2.9)

100 (72.5)
36 (26.1)
2 (1.4)

positively, and to a similar degree as the more complex DA, upon
men’s decisional uncertainty and knowledge.
The absence of an intervention effect for accuracy was unexpected given that exposure to a DA containing expressed probabilities about the chances of a particular health outcome has
previously resulted in a higher proportion of people with accurate
risk perceptions (Stacey et al., 2011). Of note is that men allocated
to the control group showed a trend for lower accuracy over time,
suggesting that information about prostate cancer screening may
not be enough to influence unrealistic expectations about risk.
Given the pattern over time for accuracy in the intervention group,
the individually tailored risk statistics may be more effective in the
short- to medium- term (Kroeze et al., 2006; Skinner et al., 2002)
when at-risk men are actively considering PSA testing, such as

Table 2
Proportion of Men Who Accessed Specific Pages of the Online Educational Materials
Type
Available to all participants
R
R
R
O
O
O
O
O
Specific to Intervention
R
R
R
R
R
R
O
Note.

Description of web page
Prostate cancer including description
and prevalence
Family history of prostate cancer
Prostate cancer screening
Prevention of prostate cancer
Possible outcomes of a PSA test
Side effects of treatment
Science studies
Further information
Tailored risk statistics
My worksheet (home page)
What is the decision I face?
Weigh the options (VCE)
How sure I feel
What are the next steps?
Example worksheets

Control, n (%)

Intervention, n (%)

Total sample, N (%)

63 (91.3)

59 (85.5)

123 (89.1)

61 (88.4)
58 (84.1)
34 (49.3)
14 (20.3)
11 (15.9)
4 (5.8)
14 (20.3)

57 (82.6)
58 (84.1)
25 (36.2)
11 (15.9)
10 (14.5)
3 (4.3)
5 (7.2)

118 (85.5)
117 (85.0)
58 (42.0)
25 (18.1)
21 (15.2)
7 (5.1)
19 (13.8)

—
—
—
—
—
—
—

54 (78.2)
45 (65.2)
44 (63.8)
35 (51.0)
40 (58.0)
40 (58.0)
22 (31.9)

—
—
—
—
—
—
—

N ⫽ 138 (n ⫽ 69 Control, n ⫽ 69 Intervention). R ⫽ requested reading; O ⫽ optional reading; VCE ⫽ values clarification exercise.

69
69

n

50 (90.9)
5 (9.1)
—
—
—
—

60 (88.2)
8 (11.8)
43 (62.3)
26 (37.7)
13 (18.8)
56 (81.2)

14.0 (18.8)
7.8 (1.9)
—
3.7 (1.9)
2.6 (0.9)

Time 2

28 (50.9)
27 (49.1)

69
69

55
52

n

35 (51.5)
33 (48.5)

36.7 (30.2)
6.4 (2.0)
—
—
—

Time 1
49
47
43

n

—
—

36 (75.0)
12 (25.0)

46 (95.8)
2 (4.2)

19 (39.6)
29 (60.4)

15.5 (20.9)
8.1 (1.2)
15.1 (16.5)

Time 3
69
68

n

18 (26.1)
51 (73.9)

39 (56.5)
30 (43.5)

62 (91.2)
6 (8.8)

27 (39.7)
41 (60.3)

38.6 (31.1)
6.6 (2.2)
—
—
—

Time 1

69
69

48
47

n

—
—

—
—

40 (85.1)
7 (14.9)

32 (68.1)
15 (31.9)

12.9 (18.8)
8.6 (1.4)
—
7.5 (3.8)
6.4 (3.2)

Time 2

Intervention

42
42
35

n

—
—

29 (69.0)
13 (31.0)

40 (95.2)
2 (4.8)

20 (47.6)
22 (52.4)

15.1 (19.4)
8.2 (1.6)
11.7 (11.8)

Time 3

Note. N ⫽ 138. PSA ⫽ prostate specific antigen. For continuous measures, higher scores indicate a higher level of decisional conflict, better knowledge, a higher level of decision regret, and more
Web screens accessed.
a
Total number of screens (Control n ⫽ 18, DA n ⫽ 25). b Total number of requested screens (Control n ⫽ 3, DA n ⫽ 9).

Continuous variables, M (SD)
Decisional conflict
Knowledge
Decision regret
No. of all screens accesseda
No. of requested screens accessedb
Dichotomous variables, frequency (%)
Accuracy of perceived risk of prostate cancer
Accurate
Inaccurate
Inclination
Leaning towards/away from PSA testing
Unsure
Screening behavior
Had a PSA test in last 12 months
Have not had a PSA test in last 12 months
Stage of decision-making
Still considering options
Have already made a choice

Description

Control

Table 3
Means and SDs for Continuous Variables and Proportions for Dichotomous Variables for Time 1, Time 2, and Time 3
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Table 4
Summary of Results of Mixed Model, Logistic, and Linear Regressions Examining the Effect of the Intervention on Change in
Decisional Conflict, Knowledge, Decision Regret, Accuracy of Perceived Risk, Inclination Regarding Prostate Specific Antigen (PSA)
Testing, and Screening Behavior
Adjusted analyses: Continuous variables
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Outcome

Exponentiated
estimate (␤)

t

p

95% Confidence
interval

0.42
1.07
1.01
0.96
1.00

⫺8.15
7.92
0.09
⫺4.96
0.07

⬍.001
⬍.001
.93
⬍.001
.95

0.34–0.52
1.05–1.09
0.75–1.36
0.95–0.98
0.97–1.04

1.29
0.98
1.06
1.08
1.00

7.38
⫺7.16
0.96
0.74
0.15

⬍.001
⬍.001
.34
.46
.88

1.20–1.38
0.98–0.99
0.94–1.19
0.87–1.34
0.99–1.01

0.34
0.45
1.30
1.37
3.28

⫺4.75
⫺3.97
5.16
3.01
4.65

⬍.001
⬍.001
⬍.001
⬍.01
⬍.001

0.22–0.53
0.31–0.67
1.18–1.44
1.12–1.69
1.98–5.43

Decisional conflicta
Time (linear)
Time (quadratic)
Group
Age (years)
Time ⫻ group
Knowledgea
Time (linear)
Time (quadratic)
Group
Language spoken at home
Time ⫻ group
Decision regreta
Group
Stage
DCS (baseline)
Education
Group ⫻ stage

Adjusted analyses: Binary variables
Outcome
Accuracyb
Time (linear)
Time (quadratic)
Group
Education
Time ⫻ group
Inclination regarding PSA testingc
Time (linear)
Group
Education
Time ⫻ group
Screening behaviord
Group
DCS (baseline)
Age (years)

B

Odds ratio

t

p

95% Confidence
interval

0.52
⫺0.05
⫺0.10
0.74
0.02

1.68
0.96
0.91
2.09
1.02

2.21
⫺2.49
⫺0.31
2.52
0.50

⬍.05
⬍.05
.76
⬍.05
.62

1.06–2.66
0.92–0.99
0.49–1.67
1.18–3.71
0.95–1.09

0.10
⫺0.03
⫺0.83
⫺0.02

1.10
0.97
0.43
0.98

0.73
⫺0.06
⫺1.65
⫺0.20

.47
.95
.10
.85

0.85–1.42
0.38–2.47
0.16–1.17
0.84–1.15

⫺0.17
⫺0.36
0.07

0.85
0.70
1.07

⫺0.57
⫺2.30
4.03

.57
⬍.05
⬍.001

0.48–1.51
0.51–0.94
1.04–1.11

Note. DCS ⫽ Decisional Conflict Scale.
a
Raw scores were log transformed before entering into the analyses. b Coded as a dichotomous variable: 0 ⫽ inaccurate, 1 ⫽ accurate. c Coded as a
dichotomous variable: 0 ⫽ unsure, 1 ⫽ I am leaning towards having a PSA test/I am leaning towards not having a PSA test. d Coded as a dichotomous
variable: 0 ⫽ I have not had a PSA test in the last 12 months, 1 ⫽ I have had a PSA test in the last 12 months. Coding for Group: 0 ⫽ control and
1 ⫽ intervention; coding for Language at Home: 0 ⫽ language other than English, 1 ⫽ English; coding for Education (coded as a dichotomous variable):
0 ⫽ nonuniversity qualified, 1 ⫽ university qualified; coding for Stage (coded as a dichotomous variable): 0 ⫽ not yet made a choice about PSA testing,
1 ⫽ I have already made a choice.

prior to or as an adjunct to a consultation with their health care
provider. This claim, however, requires further research where the
immediate and long term impact of a tailored DA on at-risk men’s
determinants of decision making about prostate cancer screening
are examined.
The VCE is an important component of the DA designed to
assist at-risk men to clarify their values regarding the possible
outcomes of PSA testing. Of the participants allocated to the
DA, only 51% completed the VCE, with a further 13% of men
accessing the worksheet but not completing it. Therefore, the
potential benefit of this component of the DA may have been

obscured. Completion of VCE in previous DA studies have
ranged from 23% among young women diagnosed with breast
cancer considering fertility options (Peate et al., 2012) to 74%
among women at high risk of breast cancer considering genetic
testing (Wakefield et al., 2008b). We did not ask participants
their reasons for (non)completion of the VCE. The most common reason for noncompletion reported in previous studies is
that a decision had already been made (Peate, Watts, & Wakefield, 2013). At baseline, 59% of our participants reported
having had at least one PSA test during the preceding 12
months, and 77.5% reported having already made a choice
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about screening; these two factors may have contributed to non
completion of the VCE. Given that explicit VCEs improve
values-based health choices (Stacey et al., 2011), the preferred
format and depth of the VCE should also be further investigated
to ensure that it is optimally utilized.
There were no significant effects of the DA on inclination
regarding PSA testing or on screening behavior. The proportion of
men who were confident about their propensity toward or away
from having a PSA test remained high for both groups over the
course of the study, and a similar proportion of men allocated to
the control materials and the DA reported having had a PSA test
after reading the online materials (75% and 69%, respectively).
These findings contrast with a recent Cochrane review evaluating
the efficacy of DAs for people facing health-related decisions
(Stacey et al., 2011). The review found that exposure to DAs
compared with usual care was associated with a reduction in the
proportion of people who remained undecided post intervention
and with fewer men electing to have PSA testing. In the current
study, there were only a small proportion of men who reported
being unsure about their leaning toward or away from PSA testing
(11.8% Control, 8.8% DA), and it may have been difficult to detect
an intervention effect given the small cell sizes. In several previous
studies, FDRs of affected men were much more likely to report
having had a PSA test compared to men in the general population
(McDowell, Occhipinti, Gardiner, & Chambers, 2012; Shah, Zhu,
Plamer, & Wu, 2007; Spencer et al., 2006). The high screening
prevalence among at-risk men may have reduced the potential for
the intervention to significantly impact screening behavior.
Stage of decision making did not influence the effect of the DA
on decisional conflict. There was, however, an intervention effect
on decision regret, which was moderated by SDM. Men who were
undecided about PSA testing at baseline who received the DA had
significantly lower levels of decision regret about PSA testing at
12 months compared with men who had already made a decision.
Decision regret is a highly negative experience, including knowledge that another choice would have resulted in a better outcome.
High levels of decision regret are associated with lower satisfaction with the decision made (Brehaut et al., 2003). Undecided men
benefitted from the intervention because they had lower levels of
regret, which suggests they were comfortable with their choice.
Undecided men allocated to the control group had the highest level
of regret at 12 months. General information about prostate cancer
screening, without personalized risk information, may impact negatively on the quality of the decision process. Participants’ satisfaction with their decision about PSA testing was not measured. A
future study is required to determine at-risk men’s satisfaction with
their screening decision immediately after tailored decision support and in the longer term, and to test the association of satisfaction with quality of the decision process.
Several limitations of the study are acknowledged. We used an
unvalidated measure of knowledge and the internal reliability of
the scale was not optimal. The measure, however, included items
assessing knowledge of the benefits and harms of PSA testing,
which is a key component of making an informed decision about
prostate cancer screening (Wolf et al., 2010). We did not include
measures of the other components of informed decision-making,
which include consistency of men’s screening decision with their
values and attitudes (Marteau, Dormandy, & Michie, 2001). We
cannot, therefore, infer whether men made an informed and

values-consistent choice about screening after reading the DA.
Perceived risk and inclination regarding PSA testing were assessed
using single items which may have reduced their reliability and
face validity.
The questionnaires involved self-report items. It was beyond the
scope of this study to verify men’s family history or their screening
behaviors with medical records. Australian men, however, are able
to provide an accurate family history of prostate cancer (Gaff et al.,
2004). The high proportion of men in the current study who
reported having had a PSA test previously, at baseline (80%) and
at follow up (72%) is comparable to the lifetime prevalence of
PSA testing among FDRs of affected Australian men aged 40 – 65
years (83.6%) (McDowell et al., 2012) and is comparable to the
prevalence rates shown for FDRs of affected men in a review of
primarily North American studies (44% to 95%; McDowell et al.,
2009). The generalizability of the study findings may be limited
because the participants were self-selected, predominantly Caucasian, and well educated.
Despite these limitations, this study is one of very few
community-based investigations in the field. It is the only randomized controlled trial, to our knowledge, to evaluate an online DA
providing individually tailored risk information designed to address the unmet screening information needs of men at risk of
developing prostate cancer. It is also the first randomized controlled trial, to our knowledge, to report men’s usage of different
components of online educational materials about prostate cancer
screening.

Conclusions
Unaffected men with a family history of prostate cancer, who
were undecided about PSA testing, benefitted most from an online
tailored prostate cancer screening DA. These men experienced
lower levels of regret following their screening decision. The DA
had no impact upon change in potential determinants of decision
making about screening, including decisional uncertainty, knowledge, and accuracy of risk perceptions, and it did not influence
screening behavior. An online tailored DA may be of optimal
benefit to at-risk men who are at the point of making a decision
about PSA testing, such as just prior to, or as an adjunct to a
consultation with a physician to discuss screening. Future prospective studies are required to explore further the specific components
of a DA that promote informed decision making about prostate
cancer screening among at-risk men.
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